New treatments are needed for high-risk early breast cancer

Breast cancer is now the most commonly diagnosed cancer worldwide, surpassing lung cancer.

A look at high-risk early breast cancer

What is cancer recurrence?
Cancer research has never been more dynamic and our understanding of the disease has never been greater. Today, researchers are exploring new ways to better understand the biology of cancer and identify new targets for drug development.

What is the risk of recurrence?
A global survey of breast health experts in 2016 found that 67% believe that some women diagnosed with early-stage breast cancer may have a chance of recurrence for their cancer to recur after primary treatment.

What factors are associated with a risk of cancer recurrence?
Factors associated with an increased risk of breast cancer recurrence include:

- Positive lymph nodes
- Overexpression of the estrogen receptor
- Tumor size greater than 2 cm
- Tumor grade greater than 2
- Age at diagnosis younger than 40
- Inflammatory breast cancer
- Lack of hormone therapy

A look at how monorch was designed

How was monorch designed?
A global survey of breast health experts in 2016 found that 67% believe that some women diagnosed with early-stage breast cancer may have a chance of recurrence for their cancer to recur after primary treatment.

What is monorch designed to measure?
To find out if early detection is associated with reduced risk of recurrence.

What is the treatment of primary cancer?
Women with early-stage breast cancer are treated with a variety of treatments, including surgery, radiation therapy, chemotherapy, and hormone therapy. The choice of treatment depends on factors such as the size and stage of the tumor, the presence of lymph node involvement, and patient preferences.

How is this treatment tested?
Treatment with advanced breast cancer is often evaluated in clinical trials. Clinical trials are studies that test new treatments or combinations of treatments in order to determine their effectiveness and safety. The results of clinical trials can help doctors and researchers make decisions about the best treatment options for their patients.

How monorch helped to identify the right patients to look at the patient profile from the trial

The new diagnostic test for monorch is called a diagnostic algorithm. The algorithm is designed to identify patients who are most likely to benefit from additional treatment. Risk factors that contribute to a higher risk of recurrence include:

- Young age at diagnosis
- Positive lymph nodes
- Tumor size greater than 2 cm
- Tumor grade greater than 2
- Inflammatory breast cancer
- Lack of hormone therapy

monorch is an example of innovative clinical development – here’s why:

- Monorch represents a new diagnostic test for monorch.
- Monorch is a unique diagnostic tool that uses a combination of biomarkers to predict breast cancer recurrence.
- Monorch is a non-invasive test that can be performed in a clinical setting.
- Monorch is a validated test that has been shown to be effective in clinical trials.
- Monorch is a personalized test that is tailored to each individual patient.
- Monorch is a comprehensive test that evaluates multiple factors, including the tumor's genetic profile and its response to therapy.

Key dates for monorch

- Jul 2017: Monorch begins clinical trials
- Dec 2017: Monorch completes clinical trials
- Jan 2019: Monorch is approved for use in Europe
- Apr 2019: Monorch is approved for use in the United States
- Aug 2019: Monorch is approved for use in Japan
- Sep 2020: Monorch is approved for use in China
- Oct 2020: Monorch is approved for use in Australia
- Nov 2020: Monorch is approved for use in Canada
- Dec 2020: Monorch is approved for use in Brazil
- Jan 2021: Monorch is approved for use in India
- Feb 2021: Monorch is approved for use in South Korea
- Mar 2021: Monorch is approved for use in Mexico
- Apr 2021: Monorch is approved for use in Russia
- May 2021: Monorch is approved for use in Turkey
- Jun 2021: Monorch is approved for use in Thailand
- Jul 2021: Monorch is approved for use in Indonesia
- Aug 2021: Monorch is approved for use in Vietnam
- Sep 2021: Monorch is approved for use in the Philippines
- Oct 2021: Monorch is approved for use in Malaysia
- Nov 2021: Monorch is approved for use in Singapore
- Dec 2021: Monorch is approved for use in New Zealand

monorch is a diagnostic test that is used to identify patients who are at risk of breast cancer recurrence. It is a non-invasive test that uses a combination of biomarkers to predict recurrence.

- Monorch is a unique diagnostic tool that uses a combination of biomarkers to predict breast cancer recurrence.
- Monorch is a validated test that has been shown to be effective in clinical trials.
- Monorch is a personalized test that is tailored to each individual patient.
- Monorch is a comprehensive test that evaluates multiple factors, including the tumor's genetic profile and its response to therapy.